What the research shows

The Menopur label describes a randomized, open-label comparison with recombinant FSH during an IVF cycle. Of 373 participants assigned to Menopur, 87 had a continuing pregnancy, defined by an ultrasound heartbeat at least ten weeks after embryo transfer. Menopur met the trial’s statistical criterion for noninferiority on that endpoint. The study concerned one fertility-treatment cycle and a specified prescription formulation. Menopur prescribing information and IVF trial.

Documented formats

Menopur is supplied as a sterile freeze-dried powder in a vial with a separate diluent. Its labeled form and potency belong to that named prescription product.

Testing and purity

Read both FSH and LH activities on the label. The manufacturer uses separate biological potency tests against reference standards. Those results describe biological responses and should be reported separately from weight and purity.

How to read a batch report

Questions about hMG (menotropins)

Why list two types of activity?

FSH and LH activity measure different biological responses. Menotropins contain both, while a comparison product can supply only recombinant FSH.

Was continuing pregnancy the same as a live birth?

The trial counted an ultrasound finding at a defined follow-up time. A live-birth endpoint requires following the pregnancy through delivery.